Panitumumab Approved as First Line Therapy for RAS Wild-type Metastatic Colorectal Cancer

Share this content:
The FDA approved the supplemental Biologics License Application for panitumumab as a first-line therapy for patients with RAS wild-type metastatic colorectal cancer.
The FDA approved the supplemental Biologics License Application for panitumumab as a first-line therapy for patients with RAS wild-type metastatic colorectal cancer.

The US Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for panitumumab, a fully humanized monoclonal anti-EGFR antibody, as a first-line therapy for patients with RAS wild-type metastatic colorectal cancer (mCRC).

The drug is approved as a monotherapy after treatment with oxaliplatin, fluoropyrimidine, and irinotecan-containing chemotherapy, or in combination with FOLFOX.

The FDA granted full approval for panitumumab as treatment for patients with wild-type KRAS mCRC based on evidence from the phase 3 PRIME (ClinicalTrials.gov Identifier: NCT00364013) and ASPECCT (ClinicalTrials.gov Identifier: NCT01001377) trials.

Data from a retrospective analysis of the PRIME study and the prospective, pre-defined analyses from the Phase 3 ‘0007 (ClinicalTrials.gov Identifier: NCT01412957) study led to approval of a refined indication for RAS wild-type mCRC.

The ‘0007 study compared the efficacy of panitumumab with best supportive care (BSC) with BSC alone in patients with chemorefractory, KRAS wild-type mCRC.

The secondary endpoint of the study demonstrated that patients with wild-type RAS (exons 2, 3, and 4 of KRAS and NRAS) mCRC treated with panitumumab and BSC resulted in a statistically significant prolongation in overall survival (OS) of 10 months vs 6.9 months among patients treated with BSC alone (hazard ratio [HR], 0.70; 95% CI, 0.53-0.93; P = .0135).

RELATED: FDA Approves NGS Panel for Gene Mutation Detection in Metastatic Colorectal Cancer

The FDA also approved a next generation sequencing (NGS) test that detects the RAS mutation status of patient tumor samples.

Adverse effects occurring among more than 20% of patients receiving panitumumab monotherapy included skin rash, paronychia, fatigue, nausea, and diarrhea.

References

  1. FDA approves Vectibix (panitumumab) for use in wild-type RAS metastatic colorectal cancer [news release]. Thousand Oaks, CA: PRNewswire; June 29, 2017. http://www.amgen.com/media/news-releases/2017/06/fda-approves-vectibix-panitumumab-for-use-in-wildtype-ras-metastatic-colorectal-cancer/. Accessed July 6, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters